Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CorMedix (CRMD) Common Equity: 2012-2024

Historic Common Equity for CorMedix (CRMD) over the last 12 years, with Dec 2024 value amounting to $84.7 million.

  • CorMedix's Common Equity rose 537.23% to $374.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $374.1 million, marking a year-over-year increase of 537.23%. This contributed to the annual value of $84.7 million for FY2024, which is N/A change from last year.
  • According to the latest figures from FY2024, CorMedix's Common Equity is $84.7 million, which was up 53.75% from $55.1 million recorded in FY2022.
  • In the past 5 years, CorMedix's Common Equity ranged from a high of $84.7 million in FY2024 and a low of $44.2 million during FY2020.
  • Moreover, its 2-year median value for Common Equity was $69.9 million (2022), whereas its average is $69.9 million.
  • As far as peak fluctuations go, CorMedix's Common Equity skyrocketed by 87.02% in 2020, and later fell by 12.32% in 2022.
  • Yearly analysis of 4 years shows CorMedix's Common Equity stood at $44.2 million in 2020, then soared by 42.00% to $62.8 million in 2021, then dropped by 12.32% to $55.1 million in 2022, then reached $84.7 million in 2024.